Evaluation of Four Human Portable Glucose Meters for Use in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2015
M. Tehranisharif1; S.I.N.A. Jahan2; S. Jamshidi2
1Clinical Pathology, Islamic Azad University-Garmsar Branch, Tehran, Iran; 2Internal Medicine, Tehran University, Tehran, Iran

Introduction

The aim of this study was to validate available human PBGMs in Iran's market for use in pet practice.

Methods

Fifty-five dogs were included in this study. The study was performed from January to February 2013. Four PBGMs, Bionime GM110® (Switzerland), Bionime GM300® (Switzerland), Accu-Chek Active® (Germany), GLUCOCARD® (Japan), were evaluated in this study. The sampling area (pinna) was pricked by a lancet and marginal bloods were evaluated with PBGMs; 3 ml of whole fresh blood was drawn from the cephalic vein of each animal and transferred to plain tubes. Immediately after blood collection, serum was harvested and transferred on ice to the laboratory and kept at -20°C until laboratory evaluation. The glucose concentrations were determined by enzymatic method (Pars Azmoon®, Iran) with semiautomated photometer (RIELE 5010, Germany). To evaluate the repeatability, precision and within-run imprecision, one sample (low, normal, high control) was analyzed 15 times, consequently with a lag time of 15 sec, and coefficient of variance (CV) was determined. In order to evaluate the correlation between glucose and PBGMs, Pearson correlation (r) was determined. To validate PBGMs, Bland-Altman plot and mean difference plot were performed. Agreement between methods was verified using the Bland-Altman difference plot. In order to validate PBGMs, at various blood levels, high- and low-level glucose controls were prepared.

Results

Table 1. Descriptive statistic of various methods (For peer review)

 

Mean ± SE (mg/dl)

Bias %

Correlation
coefficient

Coefficient of
determinant (R2)

Intercept

Slope

95% limit of agreement

Laboratory
method

115.5 ± 9.6

-

-

-

-

-

-

Bionime GM110/
venous sample

110.6 ± 9.41

-4.7%

0.98

0.96

-1.65

1.07

-8.3 to 1.1%

Bionime GM300/
venous sample

108.5 ± 9.8

-6%

0.98

0.97

-1.85

1.09

-18.9 to 6.9%

AccuCheck Active/
venous sample

99.1 ± 8.39

-15.3%

0.98

0.96

-11.3

1.06

-58.1% to 27.2%

Glucocard/
venous sample

105.1 ± 11.1

-15.2%

0.97

0.95

-24.5

1.12

-40.8% to 10.4%

Bionime GM110/
capillary sample

111.1 ± 9.43

-4.2%

0.98

0.97

-1.67

1.1

-7.9% to 0.5%

Bionime GM300/
capillary sample

110.3 ± 9.31

-4.9%

0.98

0.96

-1.67

1.11

-9.3 to 11.7%

AccuCheck Active/
capillary sample

108.7 ± 10.87

-10.4%

0.97

0.95

-18.3

1.1

-35.1% to 11.4%

Table 2. Coefficient of variation of PBGMs for the low, normal and high control solutions (For peer review)

PBGMs

Low control
CV%

Normal control
CV%

High control
CV%

Bionime GM110

4/1

4/1

3/2

Bionime GM300

4/3

4/3

4/3

AccuCheck Active

5/2

4/7

4/6

Glucocard

4/9

4/4

4/2

Results of human-based PBGMs in determining glucose levels

Discussion

The results of this study indicated that human-based PBGMs are useful for determining glucose levels in emergency situations and monitoring of diabetic dogs.

  

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

S.I.N.A. Jahan
Internal Medicine
Tehran University
Tehran, Iran


MAIN : Critical Care & Emergency Medicine : Human Portable Glucose Meters
Powered By VIN

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

mailto:vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27